全文获取类型
收费全文 | 644篇 |
免费 | 95篇 |
国内免费 | 14篇 |
专业分类
耳鼻咽喉 | 1篇 |
儿科学 | 69篇 |
妇产科学 | 5篇 |
基础医学 | 57篇 |
口腔科学 | 5篇 |
临床医学 | 98篇 |
内科学 | 188篇 |
皮肤病学 | 7篇 |
神经病学 | 18篇 |
特种医学 | 91篇 |
外科学 | 65篇 |
综合类 | 21篇 |
预防医学 | 42篇 |
眼科学 | 1篇 |
药学 | 25篇 |
肿瘤学 | 60篇 |
出版年
2022年 | 5篇 |
2021年 | 9篇 |
2019年 | 5篇 |
2016年 | 8篇 |
2015年 | 9篇 |
2014年 | 18篇 |
2013年 | 16篇 |
2012年 | 25篇 |
2011年 | 21篇 |
2010年 | 21篇 |
2009年 | 12篇 |
2008年 | 23篇 |
2007年 | 31篇 |
2006年 | 21篇 |
2005年 | 30篇 |
2004年 | 17篇 |
2003年 | 18篇 |
2002年 | 21篇 |
2001年 | 9篇 |
2000年 | 21篇 |
1999年 | 28篇 |
1998年 | 28篇 |
1997年 | 26篇 |
1996年 | 30篇 |
1995年 | 29篇 |
1994年 | 18篇 |
1993年 | 11篇 |
1992年 | 12篇 |
1991年 | 11篇 |
1990年 | 13篇 |
1989年 | 18篇 |
1988年 | 19篇 |
1987年 | 18篇 |
1986年 | 14篇 |
1985年 | 12篇 |
1984年 | 9篇 |
1983年 | 8篇 |
1982年 | 8篇 |
1981年 | 10篇 |
1980年 | 8篇 |
1979年 | 9篇 |
1978年 | 5篇 |
1976年 | 7篇 |
1975年 | 5篇 |
1974年 | 6篇 |
1973年 | 8篇 |
1971年 | 4篇 |
1969年 | 5篇 |
1968年 | 5篇 |
1967年 | 4篇 |
排序方式: 共有753条查询结果,搜索用时 0 毫秒
751.
CYP2B6 genetic variants are associated with nevirapine pharmacokinetics and clinical response in HIV-1-infected children 总被引:1,自引:0,他引:1
Saitoh A Sarles E Capparelli E Aweeka F Kovacs A Burchett SK Wiznia A Nachman S Fenton T Spector SA 《AIDS (London, England)》2007,21(16):2191-2199
BACKGROUND: Cytochrome P450 2B6 (CYP2B6)-G516T genotype is associated with altered activity of hepatic CYP2B6 and efavirenz pharmacokinetics, but the relationship between the CYP2B6-G516T genotype and nevirapine (NVP) pharmacokinetics in plasma and cerebrospinal fluid (CSF) is limited. METHODS: In 126 children who received NVP and protease inhibitors from PACTG 366 and 377 cohorts, CYP2B6 and ATP-binding cassette, sub-family B, member 1 (ABCB1) gene polymorphisms were analyzed using real-time PCR. Plasma NVP pharmacokinetics and clinical data were collected and levels of NVP in CSF were evaluated in children with HIV-related neurologic diseases. RESULTS: NVP oral clearance in children with the CYP2B6-516-T/T genotype (homozygous variant, n = 14) was 1.6 l/h per m2, which was significantly decreased compared to 2.3 l/h per m2 in those with the -G/G (wild type, n = 49, P = 0.002) and 2.1 l/h per m2 in those with the -G/T genotype (heterozygous variants, n = 63, P = 0.008). Furthermore, children with the -T/T genotype had a significant increase in CD4+ T-cell percentage (+9.0%) compared with those with the -G/G (+3.2%, P = 0.01) and -G/T genotype (+5.0%, P = 0.04) from baseline to week 12. The same trend continued at week 24. Although ABCB1-C3435T genotypes did not affect plasma NVP pharmacokinetics (P = 0.39), the NVP CSF: plasma ratios were significantly higher in children with the ABCB1-3435-C/T or -T/T genotypes (0.62, n = 9) in comparison with those with the ABCB1-3435-C/C genotype (0.43, n = 5) (P = 0.01). CONCLUSIONS: The CYP2B6-G516T genotype alters NVP pharmacokinetics and the immunologic response to NVP-containing HAART regimens in children. These data suggest that the CYP2B6-G516T is an important genetic variant that alters the pharmacokinetics and response to HAART regimens containing NVP. 相似文献
752.
Abzug MJ Pelton SI Song LY Fenton T Levin MJ Nachman SA Borkowsky W Rosenblatt HM Marcinak JF Dieudonne A Abrams EJ Pathak I;Pediatric AIDS Clinical Trials Group P Protocol Team 《The Pediatric infectious disease journal》2006,25(10):920-929
BACKGROUND: The immunogenicity and safety of 2 doses of pneumococcal conjugate vaccine (PCV) and 1 dose of pneumococcal polysaccharide vaccine (PPV) were evaluated in human immunodeficiency virus (HIV)-infected children receiving highly active antiretroviral therapy (HAART). METHODS: Children 2 to <19 years, receiving stable HAART for > or =3-6 months, with HIV RNA PCR <30,000-60,000 copies/mL, received 2 doses of PCV and 1 dose of PPV at sequential 8-week intervals. Antibodies to pneumococcal serotypes (STs) 1 (PPV only) and 6B, 14, 19F, and 23F (PCV and PPV) were measured by ELISA. RESULTS: Two hundred sixty-three subjects were enrolled, of whom 225 met criteria for inclusion in the primary dataset. Antibody concentrations were low at entry, despite previous PPV in 75%. After vaccination, 76%-96% had concentrations > or =0.5 microg/mL and 62-88% > or =1.0 microg/mL to the 5 STs (geometric mean concentrations [GMCs] = 1.44-4.25 microg/mL). Incremental gains in antibody concentration occurred with each vaccine dose. Predictors of response included higher antibody concentration at entry, higher immune stratum (based on nadir CD4% before HAART and CD4% at screening), lower entry viral RNA, longer duration of the entry HAART regimen, and age <7 years. Response was more consistently related to screening CD4% than nadir CD4%. Seven percent had vaccine-related grade 3 events, most of which were local reactions. CONCLUSIONS: Two PCVs and 1 PPV were immunogenic and safe in HIV-infected children 2 to <19 years who were receiving HAART. Responses were suggestive of functional immune reconstitution. Immunologic status based on nadir and, especially, current CD4% and control of HIV viremia were independent determinants of response. 相似文献
753.
Rosenblatt HM Song LY Nachman SA Stanley KE Krogstad PA Johnson GM Wiznia AA;Pediatric Aids Clinical Trials Group Study Team 《The Journal of allergy and clinical immunology》2005,116(3):698-703
BACKGROUND: HIV infection often impairs the immune response to childhood vaccines. OBJECTIVE: We sought to study the ability of HIV-infected children receiving highly active antiretroviral therapy (HAART) to generate a booster response to immunization with a recall antigen to which they had lost humoral immunity. METHODS: Diphtheria, tetanus toxoids, and acellular pertussis (DTaP) vaccination was given at either 16 or 36 weeks after initiation of HAART to 37 HIV-infected children 2 to 9 years of age with a history of DTaP or diphtheria-tetanus-pertussis receipt who had negative tetanus antibody titers (相似文献